U.S. Bioscience Inc. has not yet set a firm date to meet with the FDAthis month to discuss resubmission of Ethyol, Robert Kriebel, seniorvice president of finance and administration, told BioWorld onFriday. The company (AMEX:UBS) had said it hoped to meet with theagency this week to discuss continuation of clinical trials thatwould result in sufficient data to warrant approval of thechemoprotective drug, which was turned down by an advisorycommittee on Jan. 31.

(c) 1997 American Health Consultants. All rights reserved.